- Home
- ALHC vs KNSA Comparison
ALHC vs KNSA Comparison
Compare ALHC & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALHC | KNSA |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.5B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ALHC | KNSA |
|---|---|---|
| Price | $16.50 | $53.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $23.13 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 6.1M | 689.2K |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 100.00 | ★ 225.00 |
| EPS | 0.05 | ★ 0.27 |
| Revenue | ★ $3,948,719,000.00 | $677,564,000.00 |
| Revenue This Year | $33.69 | $37.48 |
| Revenue Next Year | $24.74 | $17.87 |
| P/E Ratio | $326.50 | ★ $199.89 |
| Revenue Growth | 46.06 | ★ 60.09 |
| 52 Week Low | $11.63 | $26.27 |
| 52 Week High | $23.87 | $59.87 |
Technical Indicators
Market Signals| Indicator | ALHC | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 50.44 |
| Support Level | $16.18 | $40.67 |
| Resistance Level | $18.25 | $59.87 |
| Average True Range (ATR) | 0.93 | 2.10 |
| MACD | -0.21 | -0.76 |
| Stochastic Oscillator | 17.89 | 13.23 |
Price Performance
Historical ComparisonAbout ALHC Alignment Healthcare Inc.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.